Related references
Note: Only part of the references are listed.Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
Craig R. Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Pharmacokinetics and safety of a novel influenza treatment (baloxavir marboxil) in Korean subjects compared with Japanese subjects
Yun Kim et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)
2021 Update for the Diagnosis and Management of Acute Coronary Syndromes for the Perioperative Clinician
Katherine J. Kunkel et al.
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA (2022)
Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12inhibitor
Yifan Zhang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach
Shuaibing Liu et al.
FRONTIERS IN PHARMACOLOGY (2020)
Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention
Melissa D. Klein et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Pharmacokinetics and pharmacokinetic/pharmacodynamic relationship of vicagrel, a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy Chinese subjects following single oral dosing
Cai Liu et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Development and validation of a sensitive and rapid UHPLC-MS/MS method for the simultaneous quantification of the common active and inactive metabolites of vicagrel and clopidogrel in human plasma
Cai Liu et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2018)
Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite
Dorota Danielak et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans
Jinfang Jiang et al.
FRONTIERS IN PHARMACOLOGY (2017)
METABOLISM AND PHARMACOKINETICS OF VICAGREL, A NOVEL THIENOPYRIDINE P2Y12 INHIBITOR, COMPARED WITH CLOPIDOGREL IN HEALTHY CHINESE SUBJECTS
Cai Liu et al.
DRUG METABOLISM AND PHARMACOKINETICS (2017)
Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults
Xi-Ling Jiang et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
Xi-Ling Jiang et al.
CLINICAL PHARMACOKINETICS (2015)
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients
Nicolas Simon et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis
Lanning Zhang et al.
THROMBOSIS RESEARCH (2015)
Clinical Pharmacokinetics of Clopidogrel and Its Metabolites in Patients with Cardiovascular Diseases
Marta Karazniewicz-Lada et al.
CLINICAL PHARMACOKINETICS (2014)
Effectiveness of Clopidogrel Dose Escalation to Normalize Active Metabolite Exposure and Antiplatelet Effects in CYP2C19 Poor Metabolizers
Richard B. Horenstein et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
S. A. Scott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine
Su-Jun Lee
Frontiers in Genetics (2013)
Cytochromes P450 Catalyze Both Steps of the Major Pathway of Clopidogrel Bioactivation, whereas Paraoxonase Catalyzes the Formation of a Minor Thiol Metabolite Isomer
Patrick M. Dansette et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2012)
Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model)
Jun Shen et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
A Novel Polymorphic Allele of Human Arylacetamide Deacetylase Leads to Decreased Enzyme Activity
Mai Shimizu et al.
DRUG METABOLISM AND DISPOSITION (2012)
Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects
T. Simon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis
Michael V. Holmes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
Miho Kazui et al.
DRUG METABOLISM AND DISPOSITION (2010)
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA Boxed Warning A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association
David R. Holmes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption
Justin J. Wilkins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China
Lingling Chen et al.
PHARMACOGENOMICS (2008)
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies
Radojka M. Savic et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2007)
The effect of aging on the relationship between the cytochrome P4502C19 genotype and omeprazole pharmacokinetics
Y Ishizawa et al.
CLINICAL PHARMACOKINETICS (2005)
Share Paper
